All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Infection with herpes simplex virus type 1 (HSV-1) is prevalent globally \[[@pone.0215487.ref001]\]. HSV-1 is responsible for a range of mild to serious morbidities \[[@pone.0215487.ref002], [@pone.0215487.ref003]\], with its typical clinical manifestation being orolabial herpes lesions \[[@pone.0215487.ref002], [@pone.0215487.ref004]\]. The infection, lifelong and mostly asymptomatic, is usually acquired orally and in childhood \[[@pone.0215487.ref003]\]. However, mounting evidence suggests an HSV-1 epidemiological transition in Europe and North America \[[@pone.0215487.ref004]--[@pone.0215487.ref007]\] and in Asia \[[@pone.0215487.ref008]\], associated with decreasing oral acquisition in childhood and increasing sexual acquisition (through oral sex) in adulthood \[[@pone.0215487.ref004]--[@pone.0215487.ref006]\]. In multiple Western countries, HSV-1 is already the primary cause of first episode genital herpes, surpassing the role of that of HSV-2 \[[@pone.0215487.ref004], [@pone.0215487.ref005], [@pone.0215487.ref007], [@pone.0215487.ref009]--[@pone.0215487.ref011]\]. An epidemiological transition is defined here as a significant change in the occurrence of the infection and/or its mode of transmission patterns.

HSV-1 infection is of growing interest and a focus of an international multi-sectorial effort, guided by the World Health Organization, to develop a vaccine to control infection transmission \[[@pone.0215487.ref012], [@pone.0215487.ref013]\]. To inform these global health efforts, we aimed in the present study to provide a detailed investigation of the epidemiology of HSV-1 in Latin America and the Caribbean, by conducting a comprehensive systematic review and a range of meta-analytics. Importantly, we estimated HSV-1 antibody prevalence (seroprevalence), its associations and temporal trend, and assessed the role of HSV-1 as a cause of clinically-diagnosed genital ulcer disease (GUD) and clinically-diagnosed genital herpes.

Material and methods {#sec006}
====================

The methodology of this study was adapted from that of a study investigating HSV-1 epidemiology in Asia \[[@pone.0215487.ref008]\].

Data sources and search strategy {#sec007}
--------------------------------

The systematic review and meta-analyses were guided by the Cochrane collaboration Handbook \[[@pone.0215487.ref014]\], and were reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (checklist in [S1 Table](#pone.0215487.s001){ref-type="supplementary-material"}) \[[@pone.0215487.ref015]\]. PubMed, Embase, and LILACS databases were systematically searched up to September 12, 2018. The search strategies included MeSH/Emtree and broad terms with no language or year restrictions ([S2 Table](#pone.0215487.s002){ref-type="supplementary-material"}). The definition for the Latin America and the Caribbean region included 46 countries, as listed in [S1 Box](#pone.0215487.s005){ref-type="supplementary-material"}.

Study selection and inclusion and exclusion criteria {#sec008}
----------------------------------------------------

Search results were de-duplicated using a reference manager, Endnote (Thomson Reuters, USA). Titles and abstracts were screened for relevant and potentially relevant reports, and the full-texts of these relevant or potentially relevant reports were retrieved for further screening. Bibliographies of identified relevant reports and reviews were also screened for additional potentially relevant reports. Initial screening was conducted by LS and MA, and double screening was conducted by MH.

Reports met the inclusion criteria if they reported primary data on any of three outcome measures: 1) HSV-1 seroprevalence based on a valid diagnostic method (i.e. strictly type-specific glycoprotein-G based assays), 2) proportion of HSV-1 virus isolation in clinically-diagnosed GUD, or 3) proportion of HSV-1 virus isolation in clinically-diagnosed genital herpes.

Only measures with a sample size ≥10 were included. Case reports, editorials, letters to editors, commentaries, and reviews were excluded. HSV-1 seroprevalence measures among newborns \<3 months of age were excluded, as they may reflect maternal antibodies as opposed to current infection.

In this systematic review, a "report" denotes a publication reporting a relevant outcome measure, while a "study" denotes the extracted details of an outcome measure.

Data extraction and synthesis {#sec009}
-----------------------------

Relevant reports were extracted by LS and MA, and double-extracted by MH. Extracted data included publication details, population characteristics, study methodology characteristics, and outcome measures. The extracted variables are listed in [S2 Box](#pone.0215487.s006){ref-type="supplementary-material"}. Extracted overall outcome measures for the full sample were replaced by stratified measures (if available), based on a pre-defined protocol for the stratification hierarchy, provided that the sample size in each stratum was ≥10.

For HSV-1 seroprevalence measures, extracted strata were prioritized for population type ([Fig 1](#pone.0215487.g001){ref-type="fig"}), followed by age bracket (children (≤15 years of age) *versus* adults (\>15 years of age)), and age group (≤10, 10--20, 20--30, 30--40, and ≥40 years of age). These age ranges were informed by the actually available age strata in extracted studies. For the proportions of HSV-1 virus isolation in GUD or in genital herpes, the stratification hierarchy included primary *versus* recurrent episode, followed by study site (hospital *versus* sexually transmitted infection clinic).

![Population type definition and classification.\
Abbreviation: HSV-1 = Herpes simplex virus type 1.](pone.0215487.g001){#pone.0215487.g001}

Quality assessment {#sec010}
------------------

Given the documented limitations in the sensitivity and specificity of HSV-1 serology diagnostic assays \[[@pone.0215487.ref016], [@pone.0215487.ref017]\], the validity of the type-specific diagnostic method of each study was investigated and determined in consultation with an expert advisor in HSV-1 serology, Professor Rhoda Ashley-Morrow, University of Washington, Seattle. Studies where the validity of the diagnostic method could not be confirmed, were excluded from the systematic review and meta-analytics.

Informed by the Cochrane approach \[[@pone.0215487.ref014]\], studies with valid assays were further classified into low *versus* high precision based on the number of individuals tested for HSV-1 in that study (\<100 *versus* ≥100). Moreover, studies were classified into low *versus* high risk of bias (ROB) using two quality domains: sampling method (probability-based *versus* non-probability-based sampling) and response rate (≥80% *versus* \<80%). Studies with no information on a quality domain were classified as having an "unclear" ROB for that domain.

Precision and ROB domains were included in the meta-regression analyses (as described below), to examine their associations with seroprevalence, that is the influence of the characteristics of the study methodology on observed HSV-1 seroprevalence.

Meta-analyses {#sec011}
-------------

Pooled means were estimated for HSV-1 seroprevalence and its relevant strata by population type, age bracket, age group, and year of publication category (\<2000, 2000--2009, and 2010--2018), as well as for the proportions of HSV-1 virus isolation in GUD and in genital herpes, whenever ≥3 measures were available. The estimates were calculated in R version 3.4.1 \[[@pone.0215487.ref018]\] using a DerSimonian-Laird random-effects model \[[@pone.0215487.ref019]\], as applied in the meta package \[[@pone.0215487.ref020]\]. The Freeman-Tukey type arcsine square-root transformation \[[@pone.0215487.ref021]\] was utilized to stabilize the variance of each included measure. Forest plots were produced to visualise estimates and their 95% confidence intervals (CIs).

Heterogeneity was assessed using three complementary metrics: 1) Cochrane Q statistics to test for existence of heterogeneity \[[@pone.0215487.ref019], [@pone.0215487.ref022]\], 2) I^2^ to provide the magnitude of heterogeneity that is explained by true differences in the outcome measures across studies (as opposed to being due to sampling variation) \[[@pone.0215487.ref019], [@pone.0215487.ref023]\], and 3) prediction interval to provide the range of true effect sizes of the outcome measures around the pooled mean \[[@pone.0215487.ref019], [@pone.0215487.ref023]\].

Meta-regressions {#sec012}
----------------

Associations with HSV-1 seroprevalence and sources of between-study heterogeneity were investigated using univariable and multivariable random-effects meta-regression analyses. Independent variables with a p-value ≤0.1 in univariable analysis were included in the multivariable analyses. In the multivariable models, a p-value of ≤0.05 for any given independent variable indicated strong evidence for an association with HSV-1 seroprevalence.

The included independent variables were set *a priori* and consisted of: age bracket, age group, sex, population type, country's income, assay type (Western blot, enzyme-linked immunosorbent assay, and others), sample size (\<100 *versus* ≥100), sampling method (non-probability-based *versus* probability-based), response rate (≥80 *versus* otherwise), year of publication category, year of data collection, and year of publication.

The variable of country's income (for countries with available data and per World Bank classification \[[@pone.0215487.ref024]\]) categorized the countries into upper-middle-income countries (Brazil, Colombia, Costa Rica, Jamaica, Mexico, and Peru), high-income countries (Barbados, Chile, and Argentina), and "mixed" for studies including different countries in the study sample.

Missing values for the year of data collection were imputed utilizing data for the year of publication as adjusted by the median difference between year of publication and year of data collection (for studies with non-missing data).

The meta-regressions were conducted on the log-transformed proportions (with inverse-variance weighting) in Stata/SE version 13 \[[@pone.0215487.ref025]\], using the metareg package \[[@pone.0215487.ref026]\].

Results {#sec013}
=======

Search results and scope of evidence {#sec014}
------------------------------------

[Fig 2](#pone.0215487.g002){ref-type="fig"} details the study selection process per PRISMA guidelines \[[@pone.0215487.ref015]\]. The search identified 4,023 citations (PubMed: 847, Embase: 1,329, and LILACS 1,847) of which duplicates were removed. Title and abstract screening yielded 367 relevant and potentially relevant reports. Full-text screening of these latter reports identified 29 reports that met the inclusion criteria. Four additional relevant reports \[[@pone.0215487.ref027]--[@pone.0215487.ref030]\] were identified through bibliography screening of reviews and relevant reports.

![Flow chart of article selection for the systematic review of HSV-1 infection in Latin America and the Caribbean, per the PRISMA guidelines \[[@pone.0215487.ref015]\].\
Abbreviation: HSV-1 = Herpes simplex virus type 1.](pone.0215487.g002){#pone.0215487.g002}

Extracted measures included: 35 overall HSV-1 seroprevalence measures yielding 95 stratified seroprevalence measures, five proportions of viral HSV-1 isolation in GUD, and nine proportions of viral HSV-1 isolation in genital herpes. No HSV-1 seroprevalence measure was identified among clinical children populations.

Overview of HSV-1 seroprevalence {#sec015}
--------------------------------

[Table 1](#pone.0215487.t001){ref-type="table"} lists the extracted stratified HSV-1 seroprevalence measures and their characteristics (number of measures (n) = 95). Most measures were from studies conducted prior to 2010 (n = 76; 80.0%), and were based on convenience samples (n = 68; 71.0%). Seroprevalence across all measures ranged between 7.7--100% with a median of 86.0% (n = 95; [Table 2](#pone.0215487.t002){ref-type="table"}).

10.1371/journal.pone.0215487.t001

###### Studies reporting HSV-1 seroprevalence in Latin America and the Caribbean.

![](pone.0215487.t001){#pone.0215487.t001g}

  Author, year                                       Year(s) of data collection   Country                               Study site          Study design                                   Sampling method   Population                                 HSV-1 serological assay   Sample size                                 HSV-1 seroprevalence (%)
  -------------------------------------------------- ---------------------------- ------------------------------------- ------------------- ---------------------------------------------- ----------------- ------------------------------------------ ------------------------- ------------------------------------------- --------------------------
  **Healthy children populations (n = 19)**                                                                                                                                                                                                                                                                                   
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                1--5 years old boys                        ELISA                     52                                          44.2
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                6--10 years old boys                       ELISA                     49                                          55.1
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                11--15 years old boys                      ELISA                     125                                         65.6
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                1--5 years old girls                       ELISA                     47                                          38.3
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                6--10 years old girls                      ELISA                     50                                          58.0
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                11--15 years old girls                     ELISA                     126                                         74.6
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                1--9 years old girls                       ELISA                     252                                         51.0
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                1--9 years old boys                        ELISA                     264                                         50.0
  Cowan, 2003 \[[@pone.0215487.ref045]\]             \-                           Brazil                                Outpatient clinic   CS                                             Conv              1--4 years old children                    ELISA                     232[^a^](#t001fn001){ref-type="table-fn"}   36.0
  Cowan, 2003 \[[@pone.0215487.ref045]\]             \-                           Brazil                                Outpatient clinic   CS                                             Conv              5--9 years old children                    ELISA                     232[^a^](#t001fn001){ref-type="table-fn"}   52.4
  Cowan, 2003 \[[@pone.0215487.ref045]\]             \-                           Brazil                                Outpatient clinic   CS                                             Conv              10--14 years old children                  ELISA                     233[^a^](#t001fn001){ref-type="table-fn"}   68.1
  De Salles-Gomes, 1981 \[[@pone.0215487.ref046]\]   1980                         Brazil                                Outpatient clinic   CS                                             Conv              7--11 month babies                         IF                        13                                          7.7
  De Salles-Gomes, 1981 \[[@pone.0215487.ref046]\]   1980                         Brazil                                Outpatient clinic   CS                                             Conv              1--4 years old children                    IF                        50                                          38.0
  De Salles-Gomes, 1981 \[[@pone.0215487.ref046]\]   1980                         Brazil                                Outpatient clinic   CS                                             Conv              5--9 years old children                    IF                        50                                          64.0
  De Salles-Gomes, 1981 \[[@pone.0215487.ref046]\]   1980                         Brazil                                Outpatient clinic   CS                                             Conv              10--14 years old children                  IF                        50                                          92.0
  Robinson, 2002 \[[@pone.0215487.ref047]\]          \-                           Multiple countries in South America   Community           CS                                             Conv              ≤3 years old children                      WB                        23                                          29.0
  Robinson, 2002 \[[@pone.0215487.ref047]\]          \-                           Multiple countries in South America   Community           CS                                             Conv              4--6 years old children                    WB                        56                                          72.0
  Robinson, 2002 \[[@pone.0215487.ref047]\]          \-                           Multiple countries in South America   Community           CS                                             Conv              7--9 years old children                    WB                        68                                          76.0
  Robinson, 2002 \[[@pone.0215487.ref047]\]          \-                           Multiple countries in South America   Community           CS                                             Conv              10--13 years old children                  WB                        54                                          81.0
  **Healthy adult populations (n = 51)**                                                                                                                                                                                                                                                                                      
  Arriaga-Demeza, 2008 \[[@pone.0215487.ref048]\]    2002--03                     Mexico                                Community           CS                                             Conv              18--20 years old females                   WB                        195                                         50.3
  Arriaga-Demeza, 2008 \[[@pone.0215487.ref048]\]    2002--03                     Mexico                                Community           CS                                             Conv              21--25 years old females                   WB                        153                                         53.6
  Arriaga-Demeza, 2008 \[[@pone.0215487.ref048]\]    2002--03                     Mexico                                Community           CS                                             Conv              ≥26 years old females                      WB                        31                                          74.2
  Arriaga-Demeza, 2008 \[[@pone.0215487.ref048]\]    2002--03                     Mexico                                Community           CS                                             Conv              18--20 years old males                     WB                        103                                         46.6
  Arriaga-Demeza, 2008 \[[@pone.0215487.ref048]\]    2002--03                     Mexico                                Community           CS                                             Conv              21--25 years old males                     WB                        102                                         61.8
  Arriaga-Demeza, 2008 \[[@pone.0215487.ref048]\]    2002--03                     Mexico                                Community           CS                                             Conv              ≥26 years old males                        WB                        18                                          55.6
  Morrow, 2014 \[[@pone.0215487.ref016]\]            2000--01                     Argentina                             Community           CS                                             Conv              Argentinian women                          WB                        99                                          98.9
  Morrow, 2014 \[[@pone.0215487.ref016]\]            2000--01                     Costa Rica                            Community           CS                                             Conv              Costa Rican women                          WB                        98                                          92.9
  Morrow, 2014 \[[@pone.0215487.ref016]\]            2000--01                     Mexico                                Community           CS                                             Conv              Mexican women                              WB                        100                                         98.0
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                16--20 years old males                     ELISA                     119                                         69.8
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                21--30 years old males                     ELISA                     107                                         76.6
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                31--40 years old males                     ELISA                     78                                          85.9
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                16--20 years old females                   ELISA                     128                                         75.8
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                21--30 years old females                   ELISA                     126                                         81.0
  Clemens, 2010 \[[@pone.0215487.ref043]\]           1996--97                     Brazil                                Community           CS                                             RS                31--40 years old females                   ELISA                     82                                          81.7
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                20--29 years old females                   ELISA                     252[^a^](#t001fn001){ref-type="table-fn"}   78.0
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                30--39 years old females                   ELISA                     252[^a^](#t001fn001){ref-type="table-fn"}   96.0
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                40--49 years old female                    ELISA                     252[^a^](#t001fn001){ref-type="table-fn"}   91.0
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                50--59 years old females                   ELISA                     252[^a^](#t001fn001){ref-type="table-fn"}   98.0
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                ≥60 years old females                      ELISA                     252[^a^](#t001fn001){ref-type="table-fn"}   95.0
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                20--29 years old males                     ELISA                     264[^a^](#t001fn001){ref-type="table-fn"}   91.0
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                30--39 years old males                     ELISA                     264[^a^](#t001fn001){ref-type="table-fn"}   91.0
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                40--49 years old male                      ELISA                     264[^a^](#t001fn001){ref-type="table-fn"}   93.0
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                50--59 years old males                     ELISA                     264[^a^](#t001fn001){ref-type="table-fn"}   95.0
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                ≥60 years old males                        ELISA                     264[^a^](#t001fn001){ref-type="table-fn"}   94.0
  Corona, 2010 \[[@pone.0215487.ref028]\]            2002--05                     Mexico                                Community           CS                                             Conv              ≥ 26 years old students                    ELISA                     59                                          72.9
  Corona, 2010 \[[@pone.0215487.ref028]\]            2002--05                     Mexico                                Community           CS                                             Conv              21--25 years old students                  ELISA                     412                                         59.7
  Corona, 2010 \[[@pone.0215487.ref028]\]            2002--05                     Mexico                                Community           CS                                             Conv              18--20 years old students                  ELISA                     335                                         50.1
  Cowan, 2003 \[[@pone.0215487.ref045]\]             \-                           Brazil                                Outpatient clinic   CS                                             Conv              15--19 years old adults                    ELISA                     146                                         83.3
  Cowan, 2003 \[[@pone.0215487.ref045]\]             \-                           Brazil                                Outpatient clinic   CS                                             Conv              20--29 years old adults                    ELISA                     147[^a^](#t001fn001){ref-type="table-fn"}   83.6
  Cowan, 2003 \[[@pone.0215487.ref045]\]             \-                           Brazil                                Outpatient clinic   CS                                             Conv              30--34 years old adults                    ELISA                     147[^a^](#t001fn001){ref-type="table-fn"}   95.2
  Cowan, 2003 \[[@pone.0215487.ref045]\]             \-                           Brazil                                Outpatient clinic   CS                                             Conv              35--39 years old adults                    ELISA                     147[^a^](#t001fn001){ref-type="table-fn"}   92.9
  Cowan, 2003 \[[@pone.0215487.ref045]\]             \-                           Brazil                                Outpatient clinic   CS                                             Conv              40--44 years old adults                    ELISA                     147[^a^](#t001fn001){ref-type="table-fn"}   96.0
  Cowan, 2003 \[[@pone.0215487.ref045]\]             \-                           Brazil                                Outpatient clinic   CS                                             Conv              ≥45 years old adults                       ELISA                     147[^a^](#t001fn001){ref-type="table-fn"}   94.6
  De Salles-Gomes, 1981 \[[@pone.0215487.ref046]\]   1980                         Brazil                                Outpatient clinic   CS                                             Conv              15--19 years old adults                    IF                        50                                          90.0
  De Salles-Gomes, 1981 \[[@pone.0215487.ref046]\]   1980                         Brazil                                Outpatient clinic   CS                                             Conv              20--24 years old adults                    IF                        50                                          84.0
  De Salles-Gomes, 1981 \[[@pone.0215487.ref046]\]   1980                         Brazil                                Outpatient clinic   CS                                             Conv              25--29 years old adults                    IF                        50                                          86.0
  De Salles-Gomes, 1981 \[[@pone.0215487.ref046]\]   1980                         Brazil                                Outpatient clinic   CS                                             Conv              30--34 years old adults                    IF                        60                                          98.3
  De Salles-Gomes, 1981 \[[@pone.0215487.ref046]\]   1980                         Brazil                                Outpatient clinic   CS                                             Conv              35--39 years old adults                    IF                        50                                          90.0
  De Salles-Gomes, 1981 \[[@pone.0215487.ref046]\]   1980                         Brazil                                Outpatient clinic   CS                                             Conv              ≥40 years old adults                       IF                        50                                          96.0
  Evans, 1974 \[[@pone.0215487.ref049]\]             \-                           Brazil                                Outpatient clinic   CC[^C^](#t001fn003){ref-type="table-fn"}       Conv              Healthy adults                             IF                        26                                          87.5
  Jimemez, 1979 \[[@pone.0215487.ref050]\]           \-                           Costa Rica                            Outpatient clinic   CS                                             Conv              ≥18 years old students                     NAb                       16                                          50.0
  Levett, 2005 \[[@pone.0215487.ref051]\]            \-                           Barbados                              Outpatient clinic   CS                                             Conv              Blood donors                               ELISA                     184                                         81.0
  Levett, 2005 \[[@pone.0215487.ref051]\]            \-                           Barbados                              Outpatient clinic   CS                                             Conv              Ante-natal clinic attendees                ELISA                     122                                         83.6
  Lupi, 2011 \[[@pone.0215487.ref052]\]              1996--97                     Brazil                                Outpatient clinic   Cohort[^b^](#t001fn002){ref-type="table-fn"}   Conv              Blood donors                               ELISA                     155                                         68.0
  Oberle, 1989 \[[@pone.0215487.ref053]\]            1984--85                     Costa Rica                            Community           CS                                             MCS               ≥25 years old females                      MAb                       766                                         97.1
  Patnaik, 2007 \[[@pone.0215487.ref054]\]           1985--97                     Peru                                  Community           CS                                             Conv              Peruvian women                             WB                        171                                         91.8
  Patnaik, 2007 \[[@pone.0215487.ref054]\]           1985--97                     Colombia                              Community           CS                                             Conv              Colombian women                            WB                        65                                          89.2
  Prabhakar, 1984 \[[@pone.0215487.ref055]\]         \-                           Jamaica                               Hospital            CC[^C^](#t001fn003){ref-type="table-fn"}       Conv              Healthy Jamaican women                     NAb                       60                                          38.3
  Smith, 2002 \[[@pone.0215487.ref029]\]             1996--97                     Peru                                  Hospital            CC[^C^](#t001fn003){ref-type="table-fn"}       Conv              Healthy Peruvian women                     WB                        171                                         91.8
  Smith, 2002 \[[@pone.0215487.ref029]\]             1985--88                     Colombia                              Community           CC[^C^](#t001fn003){ref-type="table-fn"}       Conv              Healthy Colombian women                    WB                        65                                          89.2
  **Healthy age-mixed populations (n = 2)**                                                                                                                                                                                                                                                                                   
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                10--19 years old females                   ELISA                     252                                         70.0
  Conde-Glez, 2013 \[[@pone.0215487.ref044]\]        2005--06                     Mexico                                Community           CS                                             RS                10--19 years old males                     ELISA                     264                                         71.0
  **Clinical adult populations (n = 7)**                                                                                                                                                                                                                                                                                      
  Calderon, 2018 \[[@pone.0215487.ref056]\]          2014--15                     Peru                                  Outpatient clinic   CS                                             Conv              Women with breast cancer                   ELISA                     44                                          88.6
  Evans, 1974 \[[@pone.0215487.ref049]\]             \-                           Brazil                                Outpatient clinic   CC[^C^](#t001fn003){ref-type="table-fn"}       Conv              Patients with Hodgkin's disease            IF                        26                                          84.4
  Moreira, 2018 \[[@pone.0215487.ref057]\]           2015--16                     Brazil                                Outpatient clinic   CC[^C^](#t001fn003){ref-type="table-fn"}       Conv              Women from a highly ZIKV-affected region   WB                        32                                          93.8
  Moreira, 2018 \[[@pone.0215487.ref057]\]           2015--16                     Brazil                                Outpatient clinic   CC[^C^](#t001fn003){ref-type="table-fn"}       Conv              Women from a highly ZIKV-affected region   WB                        160                                         95.0
  Smith, 2002 \[[@pone.0215487.ref029]\]             1996--97                     Peru                                  Hospital            CC[^C^](#t001fn003){ref-type="table-fn"}       Conv              Women with squamous-cell carcinoma         WB                        166                                         91.5
  Smith, 2002 \[[@pone.0215487.ref029]\]             1996--97                     Peru                                  Hospital            CC[^C^](#t001fn003){ref-type="table-fn"}       Conv              Women with adeno-squamous carcinoma        WB                        24                                          100
  Smith, 2002 \[[@pone.0215487.ref029]\]             1985--88                     Colombia                              Hospital            CC[^C^](#t001fn003){ref-type="table-fn"}       Conv              Women with squamous-cell carcinoma         WB                        78                                          74.4
  **Other populations (n = 16)**                                                                                                                                                                                                                                                                                              
  Levett, 2005 \[[@pone.0215487.ref051]\]            \-                           Barbados                              Outpatient clinic   CS                                             Conv              HIV-positive adults                        ELISA                     120                                         89.2
  Luchsinger, 2010 \[[@pone.0215487.ref058]\]        2005--06                     Chile                                 Outpatient clinic   CS                                             Conv              HIV-positive adults                        ELISA                     400                                         92.2
  Boulos, 1992 \[[@pone.0215487.ref059]\]            \-                           Haiti                                 Outpatient clinic   CS                                             Conv              Healthy/clinical women                     ELISA                     228                                         96.9
  Conde-Glez, 1999 \[[@pone.0215487.ref060]\]        1992                         Mexico                                Outpatient clinic   CS                                             Conv              16--22 years old FSWs                      WB                        302                                         92.7
  Conde-Glez, 1999 \[[@pone.0215487.ref060]\]        1992                         Mexico                                Outpatient clinic   CS                                             Conv              23--27 years old FSWs                      WB                        330                                         93.1
  Conde-Glez, 1999 \[[@pone.0215487.ref060]\]        1992                         Mexico                                Outpatient clinic   CS                                             Conv              28--32 years old FSWs                      WB                        187                                         94.7
  Conde-Glez, 1999 \[[@pone.0215487.ref060]\]        1992                         Mexico                                Outpatient clinic   CS                                             Conv              33--37 years old FSWs                      WB                        101                                         94.1
  Conde-Glez, 1999 \[[@pone.0215487.ref060]\]        1992                         Mexico                                Outpatient clinic   CS                                             Conv              \>37 years old FSWs                        WB                        77                                          100
  Duenas, 1972 \[[@pone.0215487.ref061]\]            \-                           Colombia                              Outpatient clinic   CS                                             Conv              14--15 years old FSWs                      NAb                       15                                          100
  Duenas, 1972 \[[@pone.0215487.ref061]\]            \-                           Colombia                              Outpatient clinic   CS                                             Conv              16--17 years old FSWs                      NAb                       56                                          100
  Duenas, 1972 \[[@pone.0215487.ref061]\]            \-                           Colombia                              Outpatient clinic   CS                                             Conv              18--19 years old FSWs                      NAb                       43                                          100
  Duenas, 1972 \[[@pone.0215487.ref061]\]            \-                           Colombia                              Outpatient clinic   CS                                             Conv              20--21 years old FSWs                      NAb                       34                                          100
  Duenas, 1972 \[[@pone.0215487.ref061]\]            \-                           Colombia                              Outpatient clinic   CS                                             Conv              22--25 years old FSWs                      NAb                       46                                          100
  Duenas, 1972 \[[@pone.0215487.ref061]\]            \-                           Colombia                              Outpatient clinic   CS                                             Conv              26--35 years old FSWs                      NAb                       95                                          100
  Duenas, 1972 \[[@pone.0215487.ref061]\]            \-                           Colombia                              Outpatient clinic   CS                                             Conv              ≥36 years old FSWs                         NAb                       54                                          100
  Lupi, 2011 \[[@pone.0215487.ref052]\]              1996--97                     Brazil                                Hospital            Cohort[^b^](#t001fn002){ref-type="table-fn"}   Conv              Men who have sex with men                  ELISA                     170                                         85.0

^a^ Study included sample size only for the total sample, but not for the strata. Each stratum sample size was set at total sample size divided by the number of strata.

^b^ The original study design of the study is prospective cohort. The included seroprevalence measures are those for the baseline measures at the onset of the study, before start of follow-up.

^c^ The original study design of the study is case-control. The included seroprevalence measures are those for each of cases and controls, separately. The population type classification was assigned based on the actual population type for each of cases and controls, separately.

Abbreviations: Conv = Convenience, CS = Cross-sectional, CC = Case-control, ELISA = Enzyme-linked immunosorbent type-specific assay, FSWs = Female sex workers, HIV = Human immunodeficiency virus, HSV-1 = Herpes simplex virus type 1, IF = Indirect immunofluorescence, MAb = Monoclonal antibody, MCS = Multistage cluster sampling, NAb = Neutralizing antibody, RS = Random sampling, WB = Western blot, ZIKV = Zika virus.

10.1371/journal.pone.0215487.t002

###### Pooled mean estimates for HSV-1 seroprevalence in Latin America and the Caribbean.
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  Population type                             Outcome measures   Samples      HSV-1 seroprevalence   Pooled mean HSV-1 seroprevalence   Heterogeneity measures                                                                                      
  ------------------------------------------- ------------------ ------------ ---------------------- ---------------------------------- ---------------------------------------------------------- ------------------------ ----------------------- ---------------
  **Healthy general populations**                                                                                                                                                                                                                   
  Children                                    19                 2,026        7.7--92.0              55.1                               57.2 (49.7--64.6)                                          190.8 (p\<0.001)         90.6 (86.8--93.3)       24.7--86.7
  Adults                                      51                 7,917        38.3--98.9             87.6                               84.5 (79.9--88.5)                                          1,323.5 (p\<0.001)       96.2 (95.7--96.8)       46.1--100
  Age-mixed                                   2                  516          70.0--71.0             70.5                               70.3 (66.2--74.2) [^d^](#t002fn004){ref-type="table-fn"}   \-                       \-                      \-
  All healthy general populations             72                 10,459       7.7--98.9              81.0                               77.7 (72.9--82.2)                                          2,269.1 (p\<0.001)       96.9 (96.5--97.3)       32.6--100
  **Clinical populations**                                                                                                                                                                                                                          
  Adults                                      7                  530          74.4--100              91.5                               90.9 (84.2--95.9)                                          25.9 (p\<0.001)          76.8 (51.5--88.9)       65.5--100
  All clinical populations                    7                  530          74.4--100              91.5                               90.9 (84.2--95.9)                                          25.9 (p\<0.001)          76.8 (51.5--88.9        65.5--100
  **Other populations**                                                                                                                                                                                                                             
  HIV positive patients                       2                  520          89.2--92.2             90.7                               91.5 (88.8--93.7)[^d^](#t002fn004){ref-type="table-fn"}    \-                       \-                      \-
  Female sex workers                          12                 1,340        93.1--100              100                                98.5 (96.4--99.8)                                          46.3 (p\<0.001)          76.2 (58.4--96.4)       88.4--100
  Men who have sex with men                   1                  170          \-                     \-                                 85.3 (79.1--90.2)[^d^](#t002fn004){ref-type="table-fn"}    \-                       \-                      \-
  Mixed healthy/clinical adults populations   1                  228          \-                     \-                                 96.9 (93.8--98.7)[^d^](#t002fn004){ref-type="table-fn"}    \-                       \-                      \-
  **Age group**                                                                                                                                                                                                                                     
  ≤10 years                                   14                 1,438        7.7--76.0              50.5                               49.7 (42.8--56.6)                                          76.4 (p\<0.001)          83.0 (72.7--89.4)       24.8--74.7
  10--20 years                                17                 2,294        46.6--100              74.6                               77.8 (67.9--84.8)                                          280.8 (p\<0.001)         94.3 (92.2--95.8)       40.0--99.5
  20--30 years                                12                 1,926        53.6--100              82.5                               82.8 (73.1--90.8)                                          276.9 (p\<0.001)         96.0 (94.5--97.2)       39.1--100
  30--40 years                                9                  1,181        81.7--98.3             92.9                               92.5 (89.4--95.1)                                          24.6 (p = 0.002)         67.4 (34.3--83.8)       81.4--99.0
  ≥40 years                                   11                 2,128        89.2--98.0             94.6                               94.2 (92.7--95.5)                                          17.5 (p = 0.064)         42.9 (0.0--71.8)        89.9--97.4
  Mixed                                       32                 4,280        38.3--100              90.3                               89.6 (85.7--93.9)                                          405.7 (p\<0.001)         92.4 (90.2--94.0)       62.9--100
  **Age bracket**                                                                                                                                                                                                                                   
  All children                                19                 2,026        7.7--92.0              55.1                               57.2 (49.7--64.6)                                          190.8 (p\<0.001)         90.6 (86.8--93.3)       24.7--86.7
  All adults                                  73                 10,690       38.3--100              91.0                               88.4 (85.2--91.2)                                          1,588.2 (p\<0.001)       95.5 (94.8--96.0)       54.8--100
  All age-mixed                               3                  531          70.0--100              71.0                               77.5 (65.8--87.5)                                          12.3 (p = 0.002)         83.7 (50.8--94.6)       0.0--100
  **Year of publication category**                                                                                                                                                                                                                  
  \<2000                                      28                 2,935        7.7--100               93.6                               90.8 (85.8--94.9)                                          394.7 (p\<0.001)         93.2 (91.2--94.7)       57.1--100
  2000--2009                                  32                 3,844        29.0--100              83.0                               80.7 (73.6--87.0)                                          847.7 (p\<0.001)         96.3 (95.6--97.0)       34.0--100
  2010--2018                                  35                 6,468        38.3--98.0             78.0                               78.8 (72.7--84.3)                                          1,113.4 (p\<0.001)       96.9 (96.4--97.4)       37.4--100
  **All studies**                             **95**             **13,335**   **7.7--100**           **86.0**                           **83.1 (79.3--86.5)**                                      **2,772.4 (p\<0.001)**   **96.6 (96.2--97.0)**   **40.2--100**

^a^ Q: The Cochran's Q statistic is a measure assessing the existence of heterogeneity in pooled outcome measures, here HSV-1 seroprevalence.

^b^ I^2^: A measure assessing the magnitude of between-study variation that is due to true differences in HSV-1 seroprevalence across studies rather than sampling variation.

^c^ Prediction interval: A measure quantifying the distribution 95% interval of true HSV-1 seroprevalence around the estimated pooled mean.

^d^ No meta-analysis was done as number of studies was \<3. If there was only one study, the reported 95% CI is the 95% CI of this study. If there were two studies, both samples were merged to yield one sample size, for which the 95% CI was calculated.

Abbreviations: CI = Confidence interval, HIV = Human immunodeficiency virus, HSV-1 = Herpes simplex virus type 1.

HSV-1 seroprevalence ranged between 7.7--92.0% with a median of 55.1% among healthy children populations (n = 19), between 38.3--98.9% with a median of 87.6% among healthy adult populations (n = 51), and between 74.4--100% with a median of 91.5% among clinical adult populations (n = 7). [Table 2](#pone.0215487.t002){ref-type="table"} lists summaries for other population categories.

Pooled mean estimates for HSV-1 seroprevalence {#sec016}
----------------------------------------------

[Table 2](#pone.0215487.t002){ref-type="table"} displays the results of the meta-analyses. The overall pooled mean HSV-1 seroprevalence (n = 95) was 83.1% (95% CI: 79.2--86.5%).

The pooled mean HSV-1 seroprevalence was 57.2% (95% CI: 49.7--64.6%) among healthy children populations, 84.5% (95% CI: 79.9--88.5%) among healthy adult populations, and 90.9% (95% CI: 84.2--95.9%) among clinical adult populations.

The pooled mean seroprevalence increased with age. It was lowest at 49.7% (n = 14; 95% CI: 42.8--56.6%) in those aged ≤10, followed by 77.8% (n = 17; 95% CI: 67.9--84.8%) in those aged 10--20, 82.8% (n = 12; 95% CI: 73.1--90.8%) in those aged 20--30, 92.5% (n = 9; 95% CI: 89.4--95.1%) in those aged 30--40, and 94.2% (n = 11; 95% CI: 92.7--95.5%) in those aged ≥40.

The pooled mean seroprevalence decreased with time. It was highest at 90.8 (95% CI: 85.8--94.9%) before the year 2000, followed by 80.7% (95% CI: 73.6--87.0%) in 2000--2009, and 78.8% (95% CI: 72.7--84.3) in 2010--2018.

Forest plots for all adult populations and all children populations can be found in [S1 Fig](#pone.0215487.s007){ref-type="supplementary-material"}. All meta-analyses showed evidence of heterogeneity ([Table 2](#pone.0215487.t002){ref-type="table"}). Heterogeneity was attributed to true variability in seroprevalence across studies rather than chance ([Table 2](#pone.0215487.t002){ref-type="table"}). The heterogeneity was affirmed by the wide prediction intervals ([Table 2](#pone.0215487.t002){ref-type="table"}).

Predictors of HSV-1 seroprevalence {#sec017}
----------------------------------

[Table 3](#pone.0215487.t003){ref-type="table"} and [S3 Table](#pone.0215487.s003){ref-type="supplementary-material"} display the results of the univariable and multivariable analyses. In the univariable analyses, age bracket, age group, sex, population type, year of publication category, year of data collection, and year of publication qualified to be included in the multivariable analysis (p\<0.1). Country's income, assay type, response rate, sample size, and sampling method all had a p-value \>0.1, and hence, were not included in the multivariable analyses.

10.1371/journal.pone.0215487.t003

###### Univariable and multivariable meta-regression models for HSV-1 seroprevalence in Latin America and the Caribbean.
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                                                          Outcome measures                   Samples        Univariable analysis   Multivariable analysis[^a^](#t003fn001){ref-type="table-fn"}                                                                            
  ------------------------------------------------------- ---------------------------------- -------------- ---------------------- -------------------------------------------------------------- ------- ------------------- --------- ------------------- --------- ---- ----
  **Population Characteristics**                          **Age bracket**                    Children       19                     2,026                                                          1.00    \-                            1.00                \-        \-   \-
  Adults                                                  73                                 10,690         1.45 (1.29--1.64)      \<0.001                                                                1.39 (1.24--1.57)   \<0.001   \-                  \-             
  Age-mixed                                               3                                  531            1.35 (1.04--1.75)      0.022                                                          35.37   1.30 (1.00--1.67)   0.042     \-                  \-             
  **Age group**                                           ≤10                                14             1,438                  1.00                                                           \-                          \-        \-                  1.00      \-   
  10--20                                                  17                                 2,294          1.44 (1.24--1.67)      \<0.001                                                                \-                  \-        1.36 (1.19--1.56)   \<0.001        
  20--30                                                  12                                 1,926          1.53 (1.31--1.79)      \<0.001                                                                \-                  \-        1.44 (1.25--1.65)   \<0.001        
  30--40                                                  9                                  1,181          1.76 (1.49--2.08)      \<0.001                                                                \-                  \-        1.70 (1.47--1.97)   \<0.001        
  ≥40                                                     11                                 2,128          1.81 (1.54--2.11)      \<0.001                                                                \-                  \-        1.81 (1.58--2.08)   \<0.001        
  Mixed                                                   32                                 4,280          1.68 (1.47--1.93)      \<0.001                                                        53.99   \-                  \-        1.54 (1.35--1.75)   \<0.001        
  **Sex**                                                 Female                             46             6,723                  1.00                                                           \-                          1.00      \-                  1.00      \-   
  Male                                                    17                                 2,771          0.86 (0.75--1.00)      0.053                                                                  0.96 (0.85--1.09)   0.572     0.97 (0.88--1.07)   0.557          
  Mixed                                                   32                                 3,751          0.93 (0.82--1.05)      0.277                                                          3.62    1.03 (0.92--1.14)   0.618     1.00 (0.92--1.09)   0.956          
  **Population type**                                     Healthy                            72             10,456                 1.00                                                           \-                          1.00      \-                  1.00      \-   
  Clinical                                                7                                  530            1.19 (0.99--1.43)      0.062                                                                  1.10 (0.93--1.29)   0.249     1.12 (0.97--1.28)   0.116          
  Other                                                   16                                 2,258          1.28 (1.12--1.45)      \<0.001                                                        17.13   1.15 (1.01--1.31)   0.035     1.16 (1.04--1.29)   0.006          
  **Country's income**                                    UMIC                               85             11,891                 1.00                                                           \-                          \-        \-                  \-        \-   
  HIC                                                     5                                  925            1.12 (0.88--1.42)      0.324                                                                  \-                  \-        \-                  \-             
  Other[^c^](#t003fn003){ref-type="table-fn"}             5                                  429            0.95 (0.73--1.22)      0.665                                                          0.00    \-                  \-        \-                  \-             
  **Study methodology characteristics**                   **Assay type**                     Western blot   27                     3,029                                                          1.00    \-                            \-                  \-        \-   \-
  ELISA                                                   46                                 8,508          0.93 (0.82--1.05)      0.277                                                                  \-                  \-        \-                  \-             
  Others                                                  22                                 1,710          1.05 (0.90--1.22)      0.496                                                          4.83    \-                  \-        \-                  \-             
  **Sample size**[^d^](#t003fn004){ref-type="table-fn"}   \<100                              13             791                    1.00                                                           \-                          \-        \-                  \-        \-   
  ≥100                                                    82                                 12,454         0.93 (0.75--1.08)      0.364                                                          0.26    \-                  \-        \-                  \-             
  **Sampling method**                                     Non-probability-based              69             8,536                  1.00                                                           \-                          \-        \-                  \-        \-   
  Probability-based                                       26                                 4,701          0.93 (0.82--1.45)      0.210                                                          1.41    \-                  \-        \-                  \-             
  **Response rate**                                       ≥80                                22             5,155                  1.00                                                           \-                          \-        \-                  \-        \-   
  Otherwise[^e^](#t003fn005){ref-type="table-fn"}         73                                 8,091          0.91 (0.80--1.03)      0.164                                                          0.93    \-                  \-        \-                  \-             
  **Temporal measures**                                   **Year of publication category**   \<2000         28                     2,935                                                          1.00    \-                            \-                  \-        \-   \-
  2000--2009                                              32                                 3,844          0.87 (0.76--0.91)      0.053                                                                  \-                  \-        \-                  \-             
  2010--2018                                              35                                 6,468          0.86 (0.75--0.70)      0.023                                                          8.67    \-                  \-        \-                  \-             
  **Year of data collection**                             95                                 13,335         0.99 (0.99--1.00)      0.047                                                          6.86    \-                  \-        \-                  \-             
  **Year of publication**                                 95                                 13,335         0.99 (0.99--0.99)      0.035                                                          7.66    0.99 (0.99--1.00)   0.389     0.99 (0.99--0.99)   0.043          

^a^ Variance explained by the final multivariable model 1 (adjusted *R*^*2*^) = 42.82%.

^b^ Variance explained by the final multivariable model 2 (adjusted *R*^*2*^) = 69.57%.

^c^ Other includes one measure of a low income country (Haiti) and the measures extracted from studies including different countries.

^d^ Sample size denotes the sample size of the study population found in the original publication.

^e^ Otherwise indicates either response rate was \<80% or response rate not included in the report.

Abbreviations: *ARR* = Adjusted risk ratio, CI = Confidence interval, ELISA = Enzyme-linked immunosorbent type-specific assay, HIC = High-income country, HSV-1 = Herpes simplex virus type 1, *RR* = Risk ratio, UMIC = Upper-middle-income country.

Since age bracket and age group are variables that are not independent of each other, two multivariable models were analyzed, each using one of these variables. For a similar consideration, the year of publication was included in the multivariable analyses, instead of year of data collection, given its more complete data. As for the multivariable analyses including the year of publication category, instead of the *linear* year of publication term, the results can be found in [S3 Table](#pone.0215487.s003){ref-type="supplementary-material"}.

The first model included age bracket, sex, population type, and year of publication. It explained 42.82% of the seroprevalence variation. In adults, seroprevalence was 1.39-fold (95% CI: 1.24--1.57) higher than that in children.

The second model included age group, sex, population type, and year of publication. It explained 69.57% of the seroprevalence variation. Compared to those aged ≤10, seroprevalence was 1.36-fold (95% CI: 1.19--1.56) higher in those aged 10--20, 1.44-fold (95% CI: 1.25--1.65) higher in those aged 20--30, 1.70-fold (95% CI: 1.47--1.97) higher in those aged 30--40, and 1.81-fold (95% CI: 1.58--2.08) higher in those aged ≥40. There was evidence here for a statistically-significant declining seroprevalence over time by 0.99-fold (95% CI: 0.99--0.99) per year, in contrast to the first model analysis ([Table 3](#pone.0215487.t003){ref-type="table"}) and the analyses including the year of publication as a category ([S3 Table](#pone.0215487.s003){ref-type="supplementary-material"}), where the evidence for the decline in sero-prevalence did not reach statistical significance.

HSV-1 virus isolation in genital ulcer disease and in genital herpes {#sec018}
--------------------------------------------------------------------

Tables [4](#pone.0215487.t004){ref-type="table"} and [5](#pone.0215487.t005){ref-type="table"} summarize the extracted proportions of HSV-1 virus isolation in GUD (n = 5) and in genital herpes (n = 9), as well as their pooled mean estimates.

10.1371/journal.pone.0215487.t004

###### Studies reporting proportions of HSV-1 virus isolation in clinically-diagnosed GUD and in clinically-diagnosed genital herpes in Latin America and the Caribbean.
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  Author, year                                                               Year(s) of data collection   Country        Study site          Study design   Sampling method   Population                               HSV-1 biological assay   Sample size   Proportion of HSV-1 isolation (%)
  -------------------------------------------------------------------------- ---------------------------- -------------- ------------------- -------------- ----------------- ---------------------------------------- ------------------------ ------------- -----------------------------------
  **HSV-1 virus isolation in clinically-diagnosed GUD (n = 5)**                                                                                                                                                                                               
  Gomes Naveca, 2013 \[[@pone.0215487.ref062]\]                              2008                         Brazil         Outpatient clinic   CS             Conv              Patients with GUD                        PCR                      15            6.6
  Gomes Naveca, 2013 \[[@pone.0215487.ref062]\]                              2008                         Brazil         Outpatient clinic   CS             Conv              Patients with primary GUD                PCR                      324           4.0
  Gomes Naveca, 2013 \[[@pone.0215487.ref062]\]                              2008                         Brazil         Outpatient clinic   CS             Conv              Patients with recurrent GUD              PCR                      95            1.1
  Noda, 2016 \[[@pone.0215487.ref063]\]                                      2012                         Cuba           Outpatient clinic   CS             Conv              Men with GUD                             PCR                      113           0.0
  Valdespino-Gomez, 1995 \[[@pone.0215487.ref064]\]                          1990                         Mexico         Community           CS             Conv              FSWs with genital ulcers                 IFA                      71            0.0
  **HSV-1 virus isolation in clinically-diagnosed genital herpes (n = 9)**                                                                                                                                                                                    
  Balachandran, 1982 \[[@pone.0215487.ref027]\]                              \-                           Puerto Ricco   Outpatient clinic   CS             Conv              STI clinic attendees                     IFA                      12            8.3
  Belli, 1990 \[[@pone.0215487.ref065]\]                                     1982--83                     Argentina      Outpatient clinic   CS             Conv              Patients with genital herpes             IFA                      25            20.0
  Do Nascimento, 1998 \[[@pone.0215487.ref030]\]                             1995                         Brazil         Outpatient clinic   CS             Conv              HIV patients with genital herpes         PCR                      36            5.0
  Hun,1987 \[[@pone.0215487.ref066]\]                                        \-                           Costa Rica     Outpatient clinic   CS             Conv              STI clinic attendees                     Culture                  12            25.0
  Prabhakar, 1987 \[[@pone.0215487.ref067]\]                                 1982                         Jamaica        Outpatient clinic   CS             Conv              STI clinic attendees                     IFA                      40            0.0
  Schultz, 1994 \[[@pone.0215487.ref068]\]                                   1988                         Chile          Outpatient clinic   CS             Conv              Pregnant women with genital herpes       DFA                      20            10.0
  Suarez, 1988 \[[@pone.0215487.ref069]\]                                    1985                         Chile          Outpatient clinic   CS             Conv              Patients with primary genital herpes     IFA                      14            28.5
  Suarez, 1988 \[[@pone.0215487.ref069]\]                                    1985                         Chile          Outpatient clinic   CS             Conv              Patients with recurrent genital herpes   IFA                      61            9.8
  Suarez, 1989 \[[@pone.0215487.ref070]\]                                    1984                         Chile          Outpatient clinic   CS             Conv              Women with genital herpes                DFA                      13            23.1

Abbreviations: Conv = Convenience, CS = Cross sectional, DFA = Direct fluorescent assay, FSWs = Female sex workers, GUD = Genital ulcer disease, HSV-1 = Herpes simplex virus type 1, IFA = Indirect immunofluorescence assay, PCR = Polymerase chain reaction, RS = Random Sampling, STI = Sexually transmitted infection.

10.1371/journal.pone.0215487.t005

###### Pooled proportions of HSV-1 virus isolation in clinically-diagnosed GUD and in clinically-diagnosed genital herpes in Latin America and the Caribbean.
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  Population type                                     Outcome measures   Samples   Proportion of HSV-1 isolation (%)   Pooled proportion of HSV-1 isolation (%)   Heterogeneity measures                                           
  --------------------------------------------------- ------------------ --------- ----------------------------------- ------------------------------------------ ------------------------ ------------------- ------------------- -----------
  Patients with clinically-diagnosed GUD              5                  618       0.0--6.6                            1.1                                        0.9 (0.0--3.6)           12.9 (p = 0.0116)   69.1 (20.7--88.0)   0.0--14.6
  Patients with clinically-diagnosed genital herpes   9                  233       0.0--28.5                           10.0                                       10.9 (4.4--19.4)         21.1 (p = 0.0069)   62.1 (21.7--81.6)   0.0--40.4

^a^ Q: The Cochran's Q statistic is a measure assessing the existence of heterogeneity in pooled outcome measures, here proportions of HSV-1 virus isolation.

^b^ I^2^: A measure assessing the magnitude of between-study variation that is due to true differences in proportions of HSV-1 virus isolation across studies rather than sampling variation.

^c^ Prediction interval: A measure quantifying the distribution 95% interval of true proportions of HSV-1 virus isolation around the estimated pooled mean.

Abbreviations: CI = Confidence interval, GUD = Genital ulcer disease, HSV-1 = Herpes simplex virus type 1.

In GUD cases, the virus isolation proportion ranged between 0.0--6.6%, with a median of 1.1% and a pooled mean of 0.9% (95% CI: 0.0--3.6%). In genital herpes cases, the proportion ranged between 0.0--28.5%, with a median of 10.0% and a pooled mean of 10.9% (95% CI: 4.4--19.4%). Both meta-analyses of proportions showed strong evidence of heterogeneity ([Table 5](#pone.0215487.t005){ref-type="table"}). Forest plots can be found in [S2 Fig](#pone.0215487.s008){ref-type="supplementary-material"}.

Quality assessment {#sec019}
------------------

A total of 31 reports were included in the systematic review, while an additional 12 reports were excluded due to potential issues in their diagnostic method ([Fig 2](#pone.0215487.g002){ref-type="fig"}).

Summary of the precision and ROB assessments are in [S4 Table](#pone.0215487.s004){ref-type="supplementary-material"}. High precision was found in the majority of studies (62.9%). High ROB in the sampling method domain was found in the vast majority of studies (94.3%). Low ROB in the response rate domain was found in 25.7% of studies, while the remaining studies had a high ROB (2.9%), or an unclear ROB (71.4%).

Since none of the study characteristics of sample size, sampling method, and response rate were found associated with HSV-1 seroprevalence ([Table 3](#pone.0215487.t003){ref-type="table"}), it is not likely that precision nor ROB have affected the results of the present study.

Discussion {#sec020}
==========

The systematic review and meta-analytics reported here indicate that HSV-1 infection is widely prevalent in Latin America and the Caribbean, at a seroprevalence level that is higher than that of the global population at 67% \[[@pone.0215487.ref001]\]. Nearly 60% of children and 90% of adults are infected, a higher seroprevalence than that in Western Countries \[[@pone.0215487.ref031]\] and Asia \[[@pone.0215487.ref008]\], though lower than that in Africa \[[@pone.0215487.ref032]\] and the Middle East and North Africa (MENA) \[[@pone.0215487.ref033]\]. Seroprevalence increased steadily with age, but most HSV-1 acquisitions still occurred in childhood (Tables [2](#pone.0215487.t002){ref-type="table"} and [3](#pone.0215487.t003){ref-type="table"}).

Age was by far the strongest predictor of infection, explaining alone \>50% of the seroprevalence variation ([Table 3](#pone.0215487.t003){ref-type="table"}). Meanwhile, sex, clinical condition, and country's income did not affect HSV-1 seroprevalence ([Table 3](#pone.0215487.t003){ref-type="table"}), in broad agreement with the results of similar studies for Africa \[[@pone.0215487.ref032]\], Asia \[[@pone.0215487.ref008]\], and MENA \[[@pone.0215487.ref033]\]. These findings affirm the notion that HSV-1 is a truly general population infection, with largely homogenous exposure risk in the population.

There was evidence for a declining seroprevalence over the last three decades, but the exact effect size of the decline and nature of the decline (linear or not) are not yet certain with currently available data (Tables [2](#pone.0215487.t002){ref-type="table"} and [3](#pone.0215487.t003){ref-type="table"} and [S3 Table](#pone.0215487.s003){ref-type="supplementary-material"}). While seroprevalence declines have been also observed in North America and Europe \[[@pone.0215487.ref031], [@pone.0215487.ref034]--[@pone.0215487.ref041]\], no evidence for such declines was found in Africa \[[@pone.0215487.ref032]\], Asia \[[@pone.0215487.ref008]\], and MENA \[[@pone.0215487.ref033]\]. The large gap in HSV-1 seroprevalence between children and adults (Tables [2](#pone.0215487.t002){ref-type="table"} and [3](#pone.0215487.t003){ref-type="table"}), supports also the interpretation of recent declines in seroprevalence, with the currently older cohorts experiencing higher infection risk in earlier times. As observed in North America \[[@pone.0215487.ref031]\], improvements in hygiene and standard of living may have driven the seroprevalence declines.

With this evidence for a possible slow transition in HSV-1 epidemiology in Latin America and the Caribbean, there is a cause for concern for genital herpes, as increasingly a larger fraction of adolescents may initiate sexual activity with no antibodies to protect them against acquiring HSV-1 sexually, and thus at risk of genital herpes. Indeed, we found evidence supporting a role for HSV-1 as the etiological cause of genital herpes (Tables [4](#pone.0215487.t004){ref-type="table"} and [5](#pone.0215487.t005){ref-type="table"}), though at rates much lower than those observed in Western countries \[[@pone.0215487.ref004], [@pone.0215487.ref005], [@pone.0215487.ref007], [@pone.0215487.ref009]--[@pone.0215487.ref011]\] and Asia \[[@pone.0215487.ref008]\].

This study has limitations. Data were available only for 14 mostly populous countries (Tables [1](#pone.0215487.t001){ref-type="table"} and [4](#pone.0215487.t004){ref-type="table"}), with no data found for the remaining 32 smaller countries. Studies varied in methods and quality and used different diagnostic assays, with potentially different sensitivity and specificity profiles \[[@pone.0215487.ref016], [@pone.0215487.ref017]\]. However, no effect was found on seroprevalence for assay type, sample size, sampling method, and response rate ([Table 3](#pone.0215487.t003){ref-type="table"}), indicating that the variability in study methods may not have impacted the results and findings of the present study.

Conclusions {#sec021}
===========

As in North America, Europe, and Asia \[[@pone.0215487.ref005], [@pone.0215487.ref007]--[@pone.0215487.ref011], [@pone.0215487.ref031], [@pone.0215487.ref035], [@pone.0215487.ref042]\], there is evidence for a possible transitioning HSV-1 epidemiology in Latin America and the Caribbean, though at a slower rate and with still limited contribution for HSV-1 in genital herpes and as a sexually transmitted infection. HSV-1 seroprevalence appears to be declining, with the younger cohorts experiencing lower infection risk than those experienced by the younger cohorts in earlier times. Yet, HSV-1 persists as a widely prevalent infection in this region, with 60% of children and 90% of adults being infected. These findings support the need for surveillance to monitor trends in seroprevalence and genital herpes etiology, and highlight the need for a vaccine to prevent infection and associated disease burden.
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